Adimmune Corporation (TPE:4142)

Market Cap	7.40B
Revenue (ttm)	1.59B
Net Income (ttm)	-282.03M
Shares Out	421.51M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,591,962
Average Volume	2,477,580
Open	17.50
Previous Close	17.50
Day's Range	17.20 - 17.55
52-Week Range	16.15 - 30.45
Beta	0.40
RSI	36.17
Earnings Date	May 15, 2025

About Adimmune

Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; and purified Tuberculin, as well as contract manufacturing services. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1965
• Employees: 564
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4142

Financial Performance

In 2024, Adimmune's revenue was 1.56 billion, a decrease of -12.78% compared to the previous year's 1.79 billion. Losses were -242.75 million, -62.06% less than in 2023.